Ignite Creation Date:
2025-12-24 @ 6:57 PM
Ignite Modification Date:
2026-06-30 @ 1:29 AM
Study NCT ID:
NCT06398457
Status:
RECRUITING
Last Update Posted:
2025-09-26
First Post:
2024-05-01
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Darzalex Faspro (Daratumumab and Hyaluronidase-fihj) Before Standard Desensitization and Allogeneic Peripheral Blood Stem Cell Transplantation in Adult Patients at High-risk for Primary Graft Failure Secondary to Donor Specific Antibodies
Sponsor:
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Hematologic Malignancy | View |
| None | Bone Marrow Transplant Rejection | View |
| None | Acute Myeloid Leukemia (AML) | View |
| None | Myelodysplastic Syndromes (MDS) | View |
| None | Acute Lymphoblastic Leukemia (ALL), Adult | View |
| None | Multiple Myeloma | View |
| None | Aplastic Anemia | View |
| None | Lymphoma | View |
| None | Non Hodgkin Lymphoma | View |
| None | Hodgkin Lymphoma | View |
| None | Chronic Myeloid Leukemia | View |
| None | Myelofibrosis | View |